Partnering In Cell And Gene Therapy Is A Unique Endeavor
Executive Summary
Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.
You may also be interested in...
US FDA’s Breakthrough And RMAT Designations: A Quick Guide
Differences in eligibility and evidentiary criteria between the US FDA's two expedited regulatory programs are reflected in a new guide; metrics to date suggest comparable success rates for designation requests under the two programs. Our infographics aid in understanding the programs.
Big Pharma Presence In Gene Therapy Dealmaking Validates Technology
For several years, smaller biotechs have been advancing gene therapies and delivery technology. Big Pharma companies have increasingly been becoming involved through deal-making, and are ready to take gene therapy to the next level.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.